Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Multiple Myeloma Patients
100%
Standard Risk
100%
Complete Response
50%
Progression-free Survival
37%
Lenalidomide
37%
Very Good Partial Response
37%
Multiple Myeloma
25%
Median Overall Survival
25%
Best Response
25%
Pretransplant
25%
Minimal Residual Disease
25%
Induction Regimen
25%
Post-transplant Management
25%
Fluorescence in Situ Hybridization
12%
Multivariable
12%
High Risk
12%
Overall Survival
12%
Chromosomal Abnormalities
12%
Overall Survival Rate
12%
Survival Outcomes
12%
Median Progression-free Survival
12%
Bortezomib
12%
Therapeutic Approaches
12%
Retrospective Analysis
12%
Favorable Outcome
12%
Single Center
12%
Melphalan
12%
Future Therapeutics
12%
Carfilzomib
12%
Negative Reactivity
12%
Del17p
12%
High-risk Cytogenetics
12%
1q21 Amplification
12%
MM Patients
12%
Multiple Data
12%
1q21 Gain
12%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Overall Survival
80%
Progression Free Survival
80%
Lenalidomide
60%
Dexamethasone
40%
Minimal Residual Disease
40%
Survival Rate
20%
Bortezomib
20%
Chromosome Aberration
20%
Melphalan
20%
Carfilzomib
20%
Medicine and Dentistry
Multiple Myeloma
100%
Autologous Hematopoietic Stem Cell Transplantation
100%
Overall Survival
50%
Progression Free Survival
50%
Lenalidomide
37%
Minimal Residual Disease
25%
Dexamethasone
25%
Survival Rate
12%
Fluorescence in Situ Hybridization
12%
Conditioning
12%
Chromosome Aberration
12%
Melphalan
12%
Bortezomib
12%
Carfilzomib
12%
Immunology and Microbiology
Multiple Myeloma
100%
Autologous Hematopoietic Stem Cell Transplantation
100%
Overall Survival
50%
Progression Free Survival
50%
Lenalidomide
37%
Dexamethasone
25%
Conditioning
12%
Survival Rate
12%
Fluorescence in Situ Hybridization
12%
Biochemistry, Genetics and Molecular Biology
Autologous Hematopoietic Stem Cell Transplantation
100%
Overall Survival
50%
Progression Free Survival
50%
Cytogenetics
25%
Dexamethasone
25%
Fluorescence in Situ Hybridization
12%
Chromosomal Abnormalities
12%
Conditioning
12%
Survival Rate
12%
Melphalan
12%
Neuroscience
Hematopoietic Cell
100%
Lenalidomide
37%
Cytogenetics
25%
Dexamethasone
25%
In Situ Hybridization
12%
Bortezomib
12%
Carfilzomib
12%
Melphalan
12%